KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) EBITDA (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of EBITDA data on record, last reported at -$214.5 million in Q4 2025.

  • For Q4 2025, EBITDA fell 93.52% year-over-year to -$214.5 million; the TTM value through Dec 2025 reached -$381.7 million, up 19.66%, while the annual FY2025 figure was -$381.7 million, 19.66% up from the prior year.
  • EBITDA reached -$214.5 million in Q4 2025 per IONS's latest filing, down from -$160.2 million in the prior quarter.
  • Across five years, EBITDA topped out at $277.5 million in Q4 2023 and bottomed at -$214.5 million in Q4 2025.
  • Average EBITDA over 5 years is -$68.4 million, with a median of -$91.1 million recorded in 2021.
  • Peak YoY movement for EBITDA: crashed 194.3% in 2022, then soared 311.55% in 2025.
  • A 5-year view of EBITDA shows it stood at $220.6 million in 2021, then plummeted by 194.3% to -$208.0 million in 2022, then surged by 233.39% to $277.5 million in 2023, then tumbled by 139.94% to -$110.8 million in 2024, then crashed by 93.52% to -$214.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$214.5 million in Q4 2025, -$160.2 million in Q3 2025, and $139.8 million in Q2 2025.